GlassScriptPhysician profile
Miles Chia-Hung Wei
NPI 1750886768
$2,867.68
in general payments reported to CMS, 2019-2025
34 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.00 · 2020: $92.62 · 2021: $112 · 2022: $210 · 2023: $257 · 2024: $951 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $257.27 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $234.74 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $200.99 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $200.66 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $170.37 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $152.48 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $92.25 | 2022-2025 | Otezla, Repatha, Evenity |
| Melinta Therapeutics, LLC | $88.84 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $83.17 | 2020-2025 | |
| Pfizer INC. | $79.59 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.90 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.95 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Shield Therapeutics INC | $61.61 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $59.86 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54.22 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $52.72 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $51.82 | 2024 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $50.54 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.38 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $45.33 | 2023-2025 | Cologuard Collection Kit |
| Baxter Healthcare | $41.63 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Axsome Therapeutics, INC. | $41.42 | 2024-2025 | Auvelity |
| Lundbeck LLC | $37.28 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $36.58 | 2023 | Myrbetriq, Veozah |
| Boston Scientific Corporation | $32.09 | 2025 | General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $30.04 | 2020-2025 | Austedo Xr |
| Corcept Therapeutics | $24.12 | 2025 | Korlym |
| Dynavax Technologies Corporation | $22.63 | 2025 | Heplisav-B |
| Mylan Specialty L.P. | $19.77 | 2021 | |
| Inspire Medical Systems, INC. | $18.11 | 2025 | Inspire |
| Allergan, INC. | $17.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.47 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $14.47 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.